Lead Product(s) : 9MW3811
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Calico Life Sciences
Deal Size : $571.0 million
Deal Type : Licensing Agreement
Alphabet's Calico Weaves Anti-Aging Deal with China's Mabwell
Details : Mabwell will grant Calico exclusive rights to develop, manufacture, and commercialize 9MW3811 for age-related diseases, in all regions except Greater China.
Product Name : 9MW3811
Product Type : Antibody
Upfront Cash : $25.0 million
June 27, 2025
Lead Product(s) : 9MW3811
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Calico Life Sciences
Deal Size : $571.0 million
Deal Type : Licensing Agreement
Lead Product(s) : IBI3002
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent Doses First Participant in Phase I of IBI3002 Bispecific Antibody in Australia
Details : IBI3002 is a global first-in-class bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). It is being evaluated for mild to moderate asthma.
Product Name : IBI3002
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : IBI3002
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GT1708F
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GT1708F is a highly active and specific inhibitor of SMO protein, which inhibits the activity of SMO protein to affect the activity of the Hedgehog pathway and the expression of its downstream related proteins, thereby treating IPF.
Product Name : GT1708F
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 10, 2023
Lead Product(s) : GT1708F
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 9MW3811
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mabwell Announces the U.S. FDA Approval of 9MW3811 for IND
Details : 9MW3811 is an innovative humanized monoclonal antibody against IL-11, which can bind IL-11 through high affinity and effectively block the activation of IL-11 downstream signal pathway being developed for fibrosis and oncology.
Product Name : 9MW3811
Product Type : Antibody
Upfront Cash : Inapplicable
June 15, 2023
Lead Product(s) : 9MW3811
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mepolizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BAT2606 a proposed biosimilar of Nucala® (mepolizumab) is an interleukin-5 (IL-5) antagonist mAB that is administered subcutaneously with a syringe or autoinjector for treatment of severe asthma, chronic rhinosinusitis with nasal, eosinophilic granuloma...
Product Name : BAT2606
Product Type : Antibody
Upfront Cash : Inapplicable
October 14, 2022
Lead Product(s) : Mepolizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TDI01
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Graviton
Deal Size : $517.5 million
Deal Type : Licensing Agreement
Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide
Details : The agreement grants development and commercialization rights for TDI01 to Graviton in all territories, excluding China.
Product Name : TDI01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 23, 2021
Lead Product(s) : TDI01
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Graviton
Deal Size : $517.5 million
Deal Type : Licensing Agreement